Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study on Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE).

Next Previous
Search
Trial Profile

Study on Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE).

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 May 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabergoline (Primary)
  • Indications Hyperprolactinaemia; Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SUCRE
  • Sponsors Pfizer

    • Most Recent Events

    • 28 Aug 2013 Interim results presented at the 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management.
    • 03 Apr 2013 Planned end date changed from 1 Mar 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 01 Mar 2013 Planned End Date changed from 1 Feb 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top